H eart failure (HF) is a major and growing public health problem in the United States that accounts for >1 million hospital admissions per year. 1 The identification of at-risk individuals may provide important opportunities to intervene early in the disease process. Of patients presenting with new-onset HF in epidemiological studies, 40% to 71% have HF with preserved rather than reduced ejection fraction (HFPEF versus HFREF). [2] [3] [4] [5] [6] [7] [8] Although the clinical course and survival after HF onset have been ascertained for both HFPEF and HFREF, 3, 5 clinical characteristics before the onset of HF have not been assessed systematically in relation to these established HF categories. Differences in risk factors preceding the onset of HFPEF versus HFREF could provide important insights into distinct pathophysiologic pathways that differ between the 2 entities. Furthermore, for persons at risk for the development of HFREF, such as those with asymptomatic left ventricular (LV) dysfunction, there is trial evidence that early treatment can improve outcomes. 9 In contrast, little is known about treatments that specifically benefit individuals at risk for or with the diagnosis of HFPEF.
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Few previous studies, to our knowledge, have examined risk factors that specifically differ in the prediction of incident HFPEF versus HFREF. Current American College of Cardiology/American Heart Association HF guidelines classify at-risk individuals as stage A HF, 11 but this group of individuals remains ill-defined with regard to type of HF. The aim of our study was, first, to examine risk factors of incident HF, and, second, to contrast clinical risk factors for incident HF with preserved versus reduced ejection fraction in a large community-based cohort with the belief that the identification of distinct risk factor clusters for HFPEF versus HFREF could have important implications for the design of clinical trials and for future therapies to prevent or treat HF.
Methods
Study Sample
The Framingham Heart Study (FHS) original and offspring cohorts have been described previously. 12, 13 Men and women in the original cohort underwent periodic cardiovascular examinations approximately every 2 years, whereas those in the offspring cohort were examined approximately every 4 years. At each visit, health history updates, physical examinations, and blood laboratory tests were performed. In total, 6340 participants (n=12 631 examinations) who did not have prevalent HF at the time of original cohort examination 16 (1979-1982, n=2000 ), examination 20 (1986-1990, n=1054 ), or examination 24 (1995-1998, n=529 ), or offspring examination 2 (1979-1983, n=2359 ), examination 4 (1987-1991, n=3385 ), or examination 6 (1995-1998, n=3304 ) were included in analyses (for details see Table S1 , available in the online-only Data Supplement). From the beginning of each follow-up period, participants were monitored for the first HF hospitalization event occurring ≤8 years later. Written, informed consent was obtained from study participants, and the research protocol was approved by the institutional review board of Boston Medical Center.
Clinical Assessment
Potential clinical predictors were assessed at the baseline examination of each 8-year follow-up period. Blood pressure (BP) was the average of 2 seated measurements obtained by an FHS physician, and hypertension was defined as a systolic BP ≥140 mm Hg, a diastolic BP ≥ 90 mm Hg, or current use of antihypertensive medication. Cardiovascular events were adjudicated by a 3-physician panel after review of medical charts. History of myocardial infarction (MI) was based on diagnostic ECG, or the combination of cardiac enzymes, and clinical presentation. History of coronary heart disease (CHD; excluding definite MI) was defined as previous clinically unrecognized MI, acute coronary insufficiency (prolonged ischemic symptoms with new ECG abnormalities in the absence of biomarker elevations indicative of infarction), or angina pectoris. Previous cerebrovascular disease was defined as previous stroke or transient ischemic attack. Occurrence of atrial fibrillation was determined after examining all of the available ECGs from FHS clinic visits and medical charts. Valvular heart disease was defined as a systolic murmur at or more than grade 3/6 or any diastolic murmur. Total cholesterol levels were obtained, and diabetes mellitus was defined as a fasting glucose ≥126 mg/dL, nonfasting blood glucose ≥200 mg/dL, or the use of insulin or oral hypoglycemic medications. Participants regularly smoking cigarettes during the year before the baseline examination were considered current smokers. LV hypertrophy was defined using previously reported ECG criteria.
14 Participants with missing covariates were excluded from the study.
Definition of Initial HF Hospitalization
At each examination, interim cardiovascular disease events were identified and medical charts obtained. Initial HF hospitalization was confirmed by a panel of 3 physicians after systematic review of outpatient and hospital records using established protocols and FHS criteria (Table S1 , available in the online-only Data Supplement). 15 In the present study, we included participants with initial HF hospitalization occurring between 1980 and 2008 when an evaluation of LV ejection fraction (LVEF) by echocardiography (85%), radionuclide angiography (10%), or ventriculography (5%) was available near the time of hospitalization. 16 Each incident HF event was classified as HFPEF (EF >45%) or HFREF (EF ≤45%) when sufficient data were available. 
Statistical Analysis
Baseline clinical characteristics were summarized separately for participants who did and did not develop HF and were further broken down by participants with HFPEF and HFREF. For HF subtype analyses, participants who developed HF that was unclassified with regard to ejection fraction were included in the group without HF. We examined cumulative incidence of HFPEF and HFREF using a Kaplan-Meier-like method while accounting for competing risks (death other HF type). 17 Analyses were conducted separately in men and women and also in subgroups with or without previous MI. Proportional hazards regression was used to model associations between clinical characteristics and incident HF. Clinical characteristics considered in multivariable models are listed in Table 1 . First, age-and sex-adjusted models were fitted for each clinical covariate and incident HF. Next, stepwise multivariable models were constructed with age and sex forced into the model. Hazards ratios for continuous variables are represented as the risk associated with a 1-SD change in the predictor. Similar models were fitted for HFREF and HFPEF. We accounted for multiple testing using Bonferroni correction: for each HF subtype, 20 covariates were tested and retained in the model at a significance level of P≤0.0025 (=0.05/20). With all of the covariates that entered into either HFPEF or HFREF in separate models, we used the Lunn-McNeil method to test whether variables were associated with differential risk for HFPEF versus HFREF. 18 In secondary analyses, epidermal growth factor receptor was considered in the multivariable model for overall HF. All of the statistical analyses were conducted with SAS version 9.2 for Windows.
Results
There were 6340 unique participants who contributed 12 631 eight-year observation periods in our analysis, with a total follow-up time of 97 808 person-years. The mean age was 60±12 years, and 54% of participants were women. A total of 512 participants developed incident HF; 55 (11%) did not undergo evaluation of LVEF-these participants did not differ from participants whose HF was classified by subtype (data not shown). Of 457 participants with HF and known LVEF, 196 (43%) were classified as HFPEF and 261 (56%) as HFREF. The overall incidence of HF was 5 cases per 1000 person-years (2 per 1000 HFPEF and 3 per 1000 HFREF). The mean follow-up time was 7.7±1.7 years. Baseline clinical characteristics are displayed by incident HF status in Table 1 (sample characteristics by HFPEF and HFREF are  displayed in Table S2 , available in the online-only Data Supplement).
Risk Factors for Incident HF
In multivariable analyses, increasing age, male sex, hypertension, higher body mass index, increasing heart rate, CHD, diabetes mellitus, smoking, valvular heart disease, lower high-density lipoprotein cholesterol, atrial fibrillation, and the presence of LV hypertrophy or left bundle-branch block all were associated with increased risk of incident HF (Table 2) . In secondary analyses, estimated glomerular filtration rate was considered as a predictor of incident HF. Baseline kidney function was available in 8116 individuals (64% of total sample size), of whom 349 developed subsequent HF. In multivariable analyses, estimated glomerular filtration rate did not factor into the final model.
Risk Factors for HFPEF and HFREF
Age-and sex-adjusted clinical predictors of new-onset HFPEF and HFREF are shown in Table 3 . With the exception of diastolic BP and cholesterol level, the majority of risk factors, including hypertension, previous MI, and diabetes mellitus, CI indicates confidence interval; HDL, high-density lipoprotein; and HR, hazard ratio. Hazard ratios are per 1 SD change in continuous variables and for the presence vs absence of dichotomous variables. Variables considered but not included in the multivariable model included systolic and diastolic blood pressure, cerebrovascular disease, total cholesterol, and right bundle-branch block. All of the covariates listed in Table 1 were considered in a stepwise selection model with retention of covariates at P<0.0025.
were significant predictors of both HFPEF and HFREF in ageand sex-adjusted analyses.
Multivariable-adjusted models for HFPEF and HFREF are shown in Table 4 . Age, diabetes mellitus, and valvular disease were significant predictors of both types of new-onset HF. The remaining risk factors were uniquely significant for either HFPEF or HFREF. Specifically, male sex, hypertension, higher heart rate, previous cardiovascular disease, higher cholesterol level, LV hypertrophy, and left bundlebranch block were associated with higher risk of HFREF. In contrast, higher BMI, smoking, and a history of atrial fibrillation increased the risk of HFPEF. Of note, hypertension and LV hypertrophy predicted HFPEF in age-and sex-adjusted analyses; however, they did not enter the multivariable model (at a P value threshold of 0.0025). Results were not materially different when we introduced systolic BP and antihypertensive therapy in place of hypertension. In exploratory analyses, at a less conservative P value threshold of 0.05, LV hypertrophy (but not hypertension) predicted HFPEF in multivariable analyses (Table S3 , available in the online-only Data Supplement).
In secondary analyses, HFPEF and HFREF were recategorized based on an LVEF cutoff of >50% or ≤50%, respectively. Results remained similar, with the exception of high-density lipoprotein cholesterol, which was a predictor of HFREF (Table S4 , available in the online-only Data Supplement).
Differential Effects of Predictors of HFPEF Versus HFREF
Despite different sets of significant variables predicting HFPEF and HFREF, only a few had differential effects on the risk of HFPEF versus HFREF (ie, acted as true effect modifiers; Table 5 ). Increasing age was associated with a higher risk of HFPEF versus HFREF (P=0.0075), whereas male sex (P=0.0003) and previous MI (P=0.0003) were associated with increased hazard for HFREF versus HFPEF. Of note, there was no evidence of a differential effect of hypertension or LV hypertrophy on HFPEF versus HFREF, although these covariates entered the multivariable model only for HFREF. Figure 1 displays the cumulative incidence of HFPEF versus HFREF by sex. Notably, the cumulative incidence of HFPEF in men and of HFPEF and HFREF in women was similar; in contrast, the cumulative incidence of HFREF in men was markedly higher. Figure 2 displays cumulative incidence by history of previous MI and shows that MI increased the risk only for HFREF.
Discussion
In a large, community-based cohort, 14 risk factors were associated with overall incident HF. Notably, distinct clusters of antecedent risk factors can be used to predict new-onset HFPEF versus HFREF. Age, diabetes mellitus, and a history of valvular disease were significant predictors of both types of new-onset HF. CI indicates confidence interval; HDL, high-density lipoprotein; HFPEF, heart failure with preserved ejection fraction; HFREF, heart failure with reduced ejection fraction; and HR, hazard ratio.
In contrast, BMI, smoking, and atrial fibrillation were predictors of HFPEF, whereas male sex, total cholesterol, heart rate, hypertension, history of cardiovascular disease, LV hypertrophy, and left bundle-branch block all increased the risk for HFREF. When examined in aggregate, we demonstrated differential effects of age, sex, and previous MI on the risk of HFPEF versus HFREF. In addition, our data suggest that the incidence of HFPEF is similar in men and women, that women are at similar risk of HFPEF and HFREF, and that men, by contrast, are at increased risk of HFREF. The findings that distinct clusters of risk factors CI indicates confidence interval; HFPEF, heart failure with preserved ejection fraction; HFREF, heart failure with reduced ejection fraction; and HR, hazard ratio. All covariates listed in Table 1 were considered in a stepwise selection model with retention of covariates at P<0.0025. BMI indicates body mass index; HFPEF, heart failure with preserved ejection fraction; HFREF, heart failure with reduced ejection fraction; and log(HR), estimate of the regression parameter.
determine risk for either HFPEF or HFREF highlight differences in the pathogenesis of the 2 subtypes of HF; this knowledge can be used in the design of clinical trials of HF prevention strategies targeting either HFREF or HFPEF.
We demonstrated previously that a constellation of 9 clinical factors (including age, heart rate, systolic BP, CHD, valvular heart disease, diabetes mellitus, cardiomegaly, LV hypertrophy, and vital capacity) predicted the 4-year risk of overall HF in participants with a history of CHD, hypertension, or valvular heart disease at baseline. 19 The present analysis extends these findings to a more contemporary and comprehensive cohort. Our group has also shown differences in clinical risk factors in HFPEF versus HFREF cross-sectionally at the time of HF presentation. 16 The current study applies this same concept to a longitudinal study design, showing that different risk factors precede and predispose to new-onset HFPEF versus HFREF. Previous longitudinal studies examining risk factors for incident HF were similarly limited by not differentiating HFPEF from HFREF. [19] [20] [21] [22] [23] [24] Other studies comparing HFPEF versus HFREF have examined clinical characteristics cross-sectionally at the time of HF presentation but not risk factors antedating the development of symptomatic HF. 5, [25] [26] [27] [28] [29] The present analysis is unique in directly comparing and contrasting antecedent risk factor profiles for incident HFPEF versus HFREF. The findings highlight important differences in risk factors routinely ascertained before the onset of each type of HF, such that a given risk factor may contribute differently to risk of HFPEF versus HFREF.
These findings are particularly relevant to individuals without known structural heart disease but at risk for HF (ie, American College of Cardiology/American Heart Association stage A HF). 11 To our knowledge, no previous prospective study has examined differences in modifiable risk factors between HFPEF and HFREF, nor has any determined whether the risk factor profile for new-onset HFPEF is distinct from that of HFREF. Our findings indicate that, in the preclinical stages of HF, distinct clusters of risk factors precede HFPEF and HFREF. As such, our findings may have important implications for targeted strategies for HF prevention. For example, angiotensin-converting enzyme inhibitors have been shown to reduce mortality in individuals with asymptomatic LV dysfunction 30 ; however, effective strategies to identify these individuals in the community have been limited. 31 The identification of specific risk factors that precede the development of HFREF could help tailor population screening strategies (eg, blood biomarkers or cardiac imaging) to identify at-risk individuals who may benefit from specific therapies.
Interestingly, previous studies have shown that women are more likely to present with HFPEF than HFREF. 3, [25] [26] [27] [28] [29] 32 However, when we examined the cumulative incidence of HFPEF and HFREF, the rates were similar in women and approximate that of HFPEF in men. The significant sexspecific difference was thus driven predominantly by an increased HFREF risk in men. This difference persisted despite adjustment for CHD history and age. Previous data from FHS participants without HF show that isolated systolic hypertension leads to concentric LV hypertrophy in women, Women whereas a pattern of eccentric hypertrophy is generally seen in men, 33 a sex difference that also was seen in experimental models. 34 This and other sex-specific responses to risk factors may contribute to the disparity in risk of HFPEF versus HFREF in men and women.
Increased BMI has been associated previously with higher risk of HF in the FHS. 35 Our data now suggest that BMI appears to be a stronger predictor of HFPEF compared with HFREF. This is supported by the observation that participants with HPFEF appear to have higher BMIs compared with HFREF in other population-based studies, 3, 4 as well as the finding that visceral adiposity is associated with LV diastolic dysfunction specifically in women. 36 The mechanisms underlying obesity and HFPEF is unclear, but are likely complex, given recent data showing a greater rate of adverse events in the lowest and highest BMI categories. 37 Previous studies have clearly shown that hypertension is a risk factor for HFPEF. 38 This is supported in our age-and sexadjusted analyses, where hypertension and LV hypertrophy predict HFPEF. It is notable that these risk factors did not enter the multivariable model for HFPEF when a strict Bonferroni correction was used. At a less conservative threshold, LV hypertrophy did predict HFPEF in multivariable analyses. However, when formally tested for effect modification, there were no differential effects of hypertension and LV hypertrophy on HF subtype. Several other limitations of our study deserve mention. The diagnosis of HF was based on HF hospitalization as the primary outcome, and this may have led to underestimation of the true incidence of HF in general and HFPEF in particular. However, because this end point was highly specific, bias of our effect estimates because of misclassification was likely minimized, despite sensitivity that may have been low. 39 Incident HFPEF versus HFREF by definition included only individuals who underwent assessment of LVEF around the time of HF diagnosis. Although the inclusion of participants with HF and unknown LVEF in the group without HF would likely have biased results toward the null, differential misclassification and bias cannot be ruled out. Of all incident HF cases, only 11% had no assessment of LV function, compared with a substantially lower proportion of patients without LV functional assessment at HF diagnosis in other studies.
3,25 LV function was assessed at the time of HF presentation, and more extensive echocardiographic data, including longitudinal changes in LVEF or diastolic function parameters, were not taken into account, potentially leading to misclassification bias. Lastly, the study sample is predominantly white, generalizability to different ethnic backgrounds may be limited, and validation in other populations is warranted. However, the clear strengths of the study were prospective ascertainment of incident HF in a large, community-based sample and the direct comparison of risk factor profiles by subtype of HF.
In conclusion, our results indicate that HF is predicted by 14 easily obtained clinical risk factors and that HFPEF and HFREF are preceded by different constellations of antecedent risk factors. These results may be particularly important with regard to further characterizing individuals at increased risk for HF. Our results indicate that the risk profiles for HFPEF and HFREF are distinct from each other years before the development of symptomatic HF. Further validation of our findings in other population-based studies is warranted. In the future, the identification of individuals at high risk for the development of specific types of HF could be used to design clinical trials of targeted prevention and treatment strategies aimed at differences in underlying risk profiles. 
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